Dermatophytic Onychomycosis Market to Grow 7.44% (2016-2020) - Key Vendors are Novartis, GlaxoSmithKline & Valeant Pharmaceuticals

Friday, March 4, 2016 3:59 PM UTC

Dublin, March 04, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/97bx43/global) has announced the addition of the "Global Dermatophytic Onychomycosis Market 2016-2020" report to their offering.

The global dermatophytic onychomycosis market is expected to grow at a CAGR of 7.44% during the period 2016-2020.

According to the report, the increase in R&D to develop drugs with disease-modifying properties and a better safety and efficacy profile drives the market.

It has been found that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. For instance, a combination of amorolfine nail lacquer and oral terbinafine, the most commonly used combination therapy, has improved clinical efficiency and is more cost-effective than terbinafine alone.

Further, the report states that the side effects associated with dermatophytic onychomycosis drugs are a challenge to the market as they hamper the acceptance of advanced drugs to treat moderate to severe dermatophytic onychomycosis.

Key vendors:

Anacor Pharmaceuticals
Galderma
Janssen Biotech
Novartis
Valeant Pharmaceuticals

Key questions answered in this report:

What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Overview: Dermatophytic onychomycosis

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by route of administration

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

Companies Mentioned:

Anacor Pharmaceuticals
Galderma
Janssen Biotech
Novartis
Valeant Pharmaceuticals
Abeona Therapeutics
Allergan
Elorac
GlaxoSmithKline
Hexima
Hisamitsu Pharmaceutical
Mayne Pharma
MediQuest Therapeutics
Meiji Seika Pharma
Merz Pharma
Moberg P

For more information visit http://www.researchandmarkets.com/research/97bx43/global



CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Dermatophytic Onychomycosis Market to Grow 7.44% (2016-2020) - Key Vendors are Novartis, GlaxoSmithKline & Valeant Pharmaceuticals

Editor's Picks

Welcome to EconoTimes